USFDA closes inspection at Shilpa Medicare Hyderabad lab
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-03-01 11:22 GMT | Update On 2024-03-21 09:36 GMT
Advertisement
Karnataka: Shilpa Medicare has announced that the United States Food and Drug Administration (USFDA) has closed the inspection at the Company's Bio Analytical Laboratory in Hyderabad without any 483 observation.
The Laboratory was inspected from 26 Feb, 2024 to 01 March, 2024.
"This is to inform you that Bio Analytical Laboratory, Shilpa Medicare Limited, Unit 7, Nacharam, Hyderabad, India was inspected by USFDA from 26 Feb, 2024 to 01 March, 2024. This unannounced USFDA Inspection has been closed without any 483 observation, stating the satisfactory compliance towards facility, systems and acceptability of data generated from this laboratory," the Company has informed in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.